

CURRICULUM VITAE

David L. DeRemer, Pharm.D, BCOP, FCCP, FHOPA

June 2019

GENERAL INFORMATION

Office Address: University of Florida College of Pharmacy
Department of Pharmacotherapy and Translational Research
HPNP 2302
Gainesville, FL 32610

Email: dderemer@cop.ufl.edu

Telephone: Office: 352-294-8891
Fax: 352-273-6485

Present Position: Clinical Associate Professor
Assistant Director of Experimental Therapeutics and Incubator (ETI)
University of Florida College of Pharmacy
University of Florida Health Cancer Center

EDUCATION

1992-1996 B.S., Biology
University of Kentucky College of Arts and Sciences

1998-2002 Doctor of Pharmacy
University of Kentucky College of Pharmacy

POSTDOCTORAL TRAINING

2002-2003 Pharmacy Practice Residency (ASHP-Accredited)
University of Kentucky Chandler Medical Center
Director: Kelly Smith Pharm.D., BCPS, FASHP, FCCP

2003-2004 Hematology-Oncology Residency (ASHP-Accredited)
University of Kentucky Chandler Medical Center
Director: Val Adams Pharm.D., FCCP, BCOP

2004-2005 Oncology Postdoctoral Fellowship
Drug Discovery/Development
University of Kentucky Chandler Medical Center
Director: Val Adams Pharm.D., FCCP, BCOP

ACADEMIC RANK AND APPOINTMENTS

9/2006-6/2012	Clinical Assistant Professor University of Georgia College of Pharmacy Department of Clinical and Administrative Pharmacy Clinical and Experimental Therapeutics (CET) Program Augusta, GA
7/2012- 8/2017	Clinical Associate Professor University of Georgia College of Pharmacy
7/2013- 8/2017	Adjunct Clinical Associate Professor Medical College of Georgia Department of Medicine, Section of Hematology/Oncology Augusta, GA
9/2017- present	Clinical Associate Professor University of Florida College of Pharmacy Department of Pharmacotherapy and Translational Research

PROFESSIONAL LICENSURE AND BOARD CERTIFICATION

2002- current	Kentucky Pharmacy Licensure (#012403)
2005- current	Georgia Pharmacy Licensure (#022799)
2006- current	Board of Pharmaceutical Specialties Board Certified Oncology Pharmacist (#506006838) Recertified by CE (2012)

PROFESSIONAL EXPERIENCE

1996-1998	Senior Lab Technician University of Kentucky College of Medicine Department of Microbiology & Immunology Jesse Sicken, Ph.D. Laboratory
1999-2002	CVS Pharmacy Intern Lexington, KY
2004-2005	Hematology/Oncology PRN Pharmacist University of Kentucky Markey Cancer Center Lexington, KY

2005-2006 Hematology/Oncology Clinical Specialist
Bone Marrow Transplant/Oncology Clinical Specialist
Medical College of Georgia (MCG Inc.)
Augusta, GA

2006- 2013 Inpatient Hematology/Oncology Clinical Specialist
Inpatient Bone Marrow Transplant/Oncology Clinical Specialist
Georgia Regents University Medical Center
(Formerly Georgia Health Sciences University and MCG Health)
Augusta, GA

2013- 2017 Outpatient BMT/Hematological Malignancies Clinical Specialist
Georgia Cancer Center
Augusta, GA

2017- present Assistant Director of the Experimental Therapeutics Incubator
University of Florida Health Cancer Center (UFHCC)
Gainesville, FL

TEACHING ACTIVITY

University of Florida College of Pharmacy

Pharm.D. Curriculum

2018-2019 PHA5782 Patient Care 2 - 6 contact hours
Lecturer- Immunotherapy, Antiemetic Pharmacology, Antiemetic Therapeutics,
NHL, Hodgkin Lymphoma
Active Learning – HL/antiemetics/Immunotherapy

PHA5784C Patient Care IV – 3 contact hours
Lecturer – Colorectal cancer screening
Active Learning – Colorectal Cancer

PHA5887C Patient Care V- 5 contact hours
Activity – Breast, Ovarian cancers, prostate

PHA5081C Complex Patients – 4 contact hours
Lecturer and ALS - Oncologic emergencies/Neutropenic Fever

PHA6449 Pharmacogenomics – 1 contact hour
Lecturer- Epigenetics

University of Georgia College of Pharmacy*Pharm.D. Curriculum*

2006-2007	<p>PHRM 3800: Clinical Applications - 8 contact hours, patient based learning</p> <p>Course Coordinator</p> <p>Facilitator – Rheumatoid arthritis</p> <p>Facilitator – Multiple myeloma</p> <p>Facilitator - Hypothyroidism</p> <p>Facilitator – Coronary Artery Disease</p> <p>Facilitator – Breast cancer</p> <p>Facilitator – Crohn’s disease</p>
2007-2008	<p>PHRM 5210: Clinical Oncology Elective – 12 contact hours, interactive cases, s seminars, experiential component</p> <p>Course Coordinator</p>
2007-2017	<p>PHRM 5870: Pharmacotherapy II – 6 contact hours, interactive cases, team- based learning</p> <p>Course coordinator (2017)</p> <p>Lecturer – Breast cancer (1 semester)</p> <p>Lecturer – Bone marrow transplantation (3 semesters)</p> <p>Lecturer – Growth factors (1 semester)</p> <p>Lecturer – CINV (6 semesters, co-mentored PGY2 resident)</p> <p>Lecturer - Systemic fungal infections (5 semesters)</p> <p>Lecturer – Oncologic emergencies (2 semesters)</p>
2007-2008	<p>PHRM 5140: Clinical Skills Lab – 12 contact hours, facilitated labs with OSCEs</p> <p>Co-Coordinator</p>
2009- 2012	<p>PHRM 4190: Cancer and Chemotherapy - 10-12 contact hours</p> <p>Co-Coordinator</p> <p>Lecturer – Chemotherapy dosing, delivery, terminology</p> <p>Lecturer – Adverse events of chemotherapy and palliation</p> <p>Lecturer – Prostate cancer</p> <p>Lecturer – NHL/Hodgkin lymphoma</p> <p>Lecturer – Pediatric malignancies</p> <p>Lecturer - Chronic leukemias</p> <p>Lecturer – Acute leukemias</p> <p>Lecturer – Colorectal cancer</p> <p>Lecturer – Lung cancer and mesothelioma</p> <p>Lecturer – Disease related symptoms</p>

2010 -2011	PHRM 5210: Landmark Clinical Studies in Oncology and Clinical Applications Seminars, interactive cases, experiential- Elective course Co-coordinator
2011-2017	PHRM 5920: Clinical Seminar- 3-5 contact hours/semester – student mentoring
2013- 2015	PHRM 5190: Anticancer therapeutics – 5-10 contact hours, didactic Lecturer – see above (PHRM 4190)
2015	PHRM 5210: Insights into Clinical Practice – 2 contact hours, small group interactive cases
2015	PHRM 5210: Resident Rounds- 12 contact hours, small group, didactic lectures Course coordinator
2016-2017	PHRM 3520: Interpreting Clinical Lab Tests – 1 contact hour, didactic Lecturer – Hematology: Red and White Blood Cells
2016	PHRM 3030: Essentials of Pharmacy Practice I – 8 contact hours, small group recitation
2017	PHRM 3040: Essentials of Pharmacy Practice II – 8 contact hours, small group recitation
2017	PHRM 4040: Essentials of Pharmacy Practice IV – 2 contact hours, skills lab Skills Lab – Handling hazardous agents
2017	PHRM 5210: Integrated Patient Cases – 2 contact hours, cases and simulated EMR

Experiential Experiences

Year	Rotations	Practice Site (s)	Students- hours
2007- 2017	5901-5908 (APPE)	<ul style="list-style-type: none"> Inpatient Hematology/Oncology BMT Outpatient Oncology 	8-10 students per year 150- 200 contact hours per rotation
2012- 2017	IPPE	<ul style="list-style-type: none"> Oncology 	8-12 students per year

Resident Graduate Curriculum

Year	Rotations	Format	Graduate students-hours
2011-2017	PHRM 7210 Advanced Pharmacy Care	Small group discussion	5-7 students- 5 contact hours/year
2011-2017 (Fall semesters)	PHRM 7810 Pharmacy Care	Direct precepting	1-2 students- > 100 contact hours
2011-2017	PHRM 7910 Adv Pharmacy Care	Direct precepting	>100 contact hours
2011- 2017	PHRM 7830 Residency Research	Research advising	1-2 students- > 100 contact hours
2011- 2017	PHRM 7840 Teaching Pharmacy Practice	Advising	1 students -> 10 contact hours
2011- 2017	PHRM 7940 Teaching Pharmacy Practice PGY2	Advising	1-2 students -> 10 contact hours
2012-2013	PHRM 7210 Special Topics PGY2 Oncology Residents	Interactive cases	10 contact hours

Medical College of Georgia College of Allied Health- Physician Assistant Program

2009-2015 *Chemotherapy 101*
Chemotherapy Induced Nausea-Vomiting
 Format: Didactic lectures

Medical College of Georgia College of Nursing

2008-2012 NSG 7430 - Pharmacology for Advanced Practice Nurses
Pain Management (3 contact hours annually)
Adjuvant Treatments in Cancer (3 contact hours annually)

University of Kentucky College of Pharmacy

Spring 2004 Integrated Applied Therapeutics II (PHR 963)
 (2 contact hours)

Fall 2004 Integrated Applied Therapeutics I (PHR 962)
 (2 contact hours)

Fall 2003 Contemporary Aspects of Pharmacy Practice (PHR 939)
 (8 contact hours)

Spring 2002 Contemporary Aspects of Pharmacy Practice (PHR 919)

(8 contact hours)

University of Kentucky College of Allied Health Sciences-Physician Assistant

Spring 2003

Pharmacology Course
Immunomodulating Agents
Antineoplastic Agents
 (2 contact hours)

POSTGRADUATE TRAINEES**UGA –AU PGY2 Oncology Pharmacy Residency Program Director**

Year	Graduate Resident	First Clinical Position
2011-2012	Katerina Katsanevas Butler, Pharm.D BCOP	Oncology Clinical Specialist VA Medical Center Salt Lake City, UT
2012-2013	Stephen Clark, Pharm.D. BCOP	BMT Clinical Specialist University of North Carolina Chapel Hill, NC
2012-2013	Alison Steinbach, Pharm.D	Outpatient Clinical Specialist West Penn Allegheny Hospital Pittsburgh, PA
2013-2014	Megan Hartranft, Pharm.D. BCPS, BCOP	Clinical Assistant Professor Rosalind Franklin College of Pharmacy Rush Cancer Center Chicago, IL
2014-2015	Sarah Evans, Pharm.D. BCOP	Outpatient Clinical Specialist The Ohio State Medical Center James Cancer Center Columbus, OH
2015- 2016	Julianne Orr, Pharm.D. BCOP	Outpatient Clinical Specialist Indiana Health Indianapolis, IN
2016-2017	Ben Andrick, Pharm.D. BCOP	BMT Clinical Specialist Geisinger Health System Danville, PA
7/2017-8/2017	Morgan Gwynn, Pharm.D.	Melanoma & Thoracic Clinical Specialist UNC Medical Center Chapel Hill, NC

UGA Clinical and Experimental Therapeutics (CET) Clinical Program Training

Year	Graduate Student	Rotation
2010	Belal Al-Husein, M.S.	Inpatient Oncology

2012	Ahmed Al-Azayzih, Pharm.D. BCOP	Inpatient Oncology
2014	Harika Sabbineni, B.Pharm.	Outpatient BMT

UGA Clinical and Experimental Therapeutics Dissertation Committee Member

Year	Graduate Student	Thesis Title
2010-2011	Belal Al-Husein, M.S.	Molecular mechanisms regulating simvastatin-mediated inhibition of prostate cancer cellular functions <i>in vitro</i> and tumor growth <i>in vivo</i>
2011-2012	Ahmed Al-Azayzih, Pharm.D. BCOP	Role of Akt in myofibroblast differentiation leading to pulmonary vascular remodeling and idiopathic pulmonary fibrosis

PGY1 Pharmacy Residency Precepting

Year	Graduate Resident	Rotation
2010-2011	Katerina Katsanevas, Pharm.D. BCOP	Inpatient hematology/oncology
2009-2010	Karly O'Brien, Pharm.D.	Inpatient hematology/oncology
2009-2010	Ashley Richard, Pharm.D.	Inpatient hematology/oncology
2009-2010	Amber Bradley, Pharm.D. BCOP	Inpatient hematology/oncology
2008-2009	Neha Dosi, Pharm.D.	Inpatient hematology/oncology
2008-2009	Evelina Maciuleviciute, Pharm.D.	Inpatient hematology/oncology
2007-2008	Tim Robinson, Pharm.D. BCPS	Inpatient hematology/oncology
2007-2008	Kinjal Vikal, Pharm.D.	Inpatient hematology/oncology

CERTIFICATIONS/OTHER TRAINING

2018	NIH – Principles of Clinical Pharmacology Certificate
2015	Chairs and Academic Administrators Management Program (CAAMP) Academy for Academic Leadership Atlanta, GA

2014	ACCP Focused Investigator Training (FIT) Program Athens, GA
2012	CITI- Collaborative IRB Training Initiative Certification Georgia Health Sciences University Refresher Course Completed (2006, 2009)
2012	CITI Certification for Institutional Review Board Members Georgia Health Sciences University
2007	Biosafety Training Certification Medical College of Georgia
2006	Saf-T-Pak Inc Biological Specimens Certification Recertification (2015- Safe Transports of Biological Substances) Medical College of Georgia
2004	Scholarship of Teaching and Learning Certificate Program University of Kentucky Chandler Medical Center
2003	Navigating the Clinical Research Process Investigator Training University of Kentucky Chandler Medical Center
2003	Advanced Cardiac Life Support Certification University of Kentucky Chandler Medical Center
2002	Adult Immunizations Certification University of Kentucky College of Pharmacy

PRESENTATIONS

National

1. *Schedule-dependent Synergism and Antagonism between Paclitaxel and Topotecan in Human Ovarian Cancer Cell Lines in vitro*. Scientific Paper Platform Presentation. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting; San Francisco, CA. October 2005
2. *Strategies for Success in Pharmacy Board Certification: A Panel Discussion*. Panel – Smith KM, Canada TW, Divine H, Jennings HR. Presented at the 42nd American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting; Las Vegas, NV. December 2, 2007

3. *Hodgkin Lymphoma* BCOP Recertification Presentation. Presented at the 9th Annual Hematology Oncology Pharmacists Association (HOPA) Annual Meeting; Los Angeles, CA. March 2013.
4. *Trending now #ExcellenceInPrecepting – effective ways to incorporate social media into clinical practice*. Co-presenters- Clark S and Hartranft M. Presented at the ASHP National Pharmacy Preceptors Conference; Washington DC. August 22, 2013.
5. *Have you submitted that paper yet? Successfully precepting student and resident research projects*. Co-presenters- May JR, Phillips BJ, Phillips M. Presented at the ASHP National Pharmacy Preceptors Conference; Washington DC. August 23, 2013.
6. *Hodgkin Lymphoma* BCOP Recertification Presentation. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Albuquerque, NM. October 15, 2013.
7. *Hodgkin Lymphoma* BCOP Recertification Presentation. Presented at ASHP Annual Meeting Orlando, FL. December 10, 2013.
8. *Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcomes and drug response*. The Great Eight Best Paper Presentations Series. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Austin, TX. October 13, 2014
9. *Hematology/Oncology PRN Focus Session: Confronting the Global Epidemic of Human Papillomavirus (HPV) and Associated Malignancies*. Moderator at Global American College of Clinical Pharmacy (ACCP) Annual Meeting San Francisco, CA. October 19, 2015.
10. *Recent Advances in the Treatment and Management of Lymphomas*. Presented at HOPA BCOP Updates Course Orlando, FL. July 16, 2016.
11. *Malignancy in the HIV Patient*. Presented at the ACCP Annual Meeting Hollywood, FL. October 24, 2016.
12. *Oral Chemotherapy Education*. Presented at the National Community Oncology Dispensing Association (NCODA) Annual Summit Atlanta, GA. October 29, 2016.
13. *Managing Acute Lymphoblastic Leukemia (ALL): A Review on Diagnosis and Clinical Considerations for the Healthcare Professional*. Webinar provided by Specialty Pharma Education Center, 2016.
14. *Cracking the Code on Oral Chemotherapy: Pharmacotherapy Management and Counseling Strategies*. Presented at the ACCP Annual Meeting Phoenix, AZ. October 10th, 2017.

15. *Oral Chemotherapy Education*. Presented at the NCODA Annual Meeting Orlando, FL. October 19, 2017.
16. *Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma*. ASHP Advantage Webinar. October 26, 2017.
17. *Embracing the Mid-Career Crisis: Pivoting to New Career Challenges*. Presented at the HOPA Annual Conference in Denver, CO. March 24, 2018.
18. *Exploring Treatment Options for Patients with Acute Lymphoblastic Leukemia (ALL)*. Pharmacy Times CE Webinar. May 22, 2018.
19. *Oncologic Pharmacology – Alkylating Agents*. ASCO University Webinar. September 2018.
20. *Oncologic Pharmacology – Topoisomerase Inhibitors and Antibiotics*. ASCO University Webinar. September 2018.
21. *Oncologic Pharmacology – Antimicrotubule Agents*. ASCO University Webinar. September 2018.
22. *Updates from the 2018 American Society of Clinical Oncology Meeting – Hematology Focused*. HOPA Emerging Issues in Oncology Webinars. September 27, 2018.
23. *Precision Immunotherapy*. Presented at the ACCP Annual Meeting Seattle, WA. October 20th, 2018.

Regional

1. *The Specific Role of 92kDa Type IV Collagenase in Metastatic Tumor Cells* Howard Hughes Research Award Winners Presentation. Kentucky/Tennessee Academy of Science Joint Meeting Bowling Green, KY. May 1996
2. *Erythropoietin Response in Patients Concurrently Receiving Capecitabine* ACPE accredited continuing education program. Southeastern Residency Conference University of Georgia. Athens, GA. May 2003
3. *Thymoquinone: Analytical Method and Assay Validation*. Southeastern Residency Conference. ACPE accredited continuing education program. University of Georgia. Athens, GA. May 2004
4. *Selected Overview of Recently Approved Oncology Agents: Targeting New Molecular Targets* Kentucky Health System Pharmacists (KSHP) Annual Meeting. ACPE accredited continuing education program.. Lexington, KY. September 2004.
5. *New Oncology Agents*. Georgia Health System Pharmacists (GHSP) Fall Annual Meeting

ACPE accredited continuing education program. Helen, GA October 2006.

6. *The Generational Joust: Strategies for Boomers and GenXers as the Millennials Enter the Profession of Pharmacy.* Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL June 2008
7. *Breast and Gynecological Cancers.* South Carolina Pharmacists Association Summer Meeting ACPE accredited continuing education program. Hilton Head, SC June 2010.
8. *Managing Vascular Complications Associated with Novel Targeted Chemotherapy Agents* Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2012.
9. *Confronting the Rise of Cancers in the HIV Population.* Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2017.
10. *Mid-Career Crisis and Burnout: Refocus or Transition to New Challenges.* (GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island, FL July 2018.

State/Local

1. *Angiogenesis: Switching On/Off Molecular Targets for Differing Clinical Outcomes* ACPE accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA. February 2006.
2. *What's "Hot" in the Treatment of Leukemias.* ACPE accredited continuing education program MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2006.
3. *Perspective of a New Generation Xer Professor- Challenges and Strategies of Teaching the Millennials.* ACPE accredited continuing education program/ MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2007.
4. *Neurotoxicity of Chemotherapeutic Agents.* MCG Neurology Resident Ground Rounds Series Medical College of Georgia, Augusta, GA. February 2008.
5. *Recent Significant Advances in Oncology.* ACPE accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah and Athens, GA. April 2009.
6. *Making it less MUDdy: Understanding Matched Unrelated Donor Bone Marrow Transplants.* ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. April 2011

7. *Maintaining the Maintenance: Is this the Future of Cancer Therapy*. ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. October 2012.
8. *Recent Advances in Cancer Immunotherapy: Developing a Killer Instinct*. ACPE accredited continuing education program. GRU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah, Athens, and Albany, GA. September 2014.
9. *Hematopoietic Growth Factors*. Augusta University Division of Hematology/Oncology Fellows Grand Rounds. February 8, 2017.
10. *Immunotherapy*. UF Health Clinical Trials Office (CTO) Grand Rounds. September 21, 2018.
11. *Spotlight on Oncology Pharmacy*. UF Pre-Pharmacy Society. December 3, 2018.

PEER-REVIEWED PUBLICATIONS

1. Sisken J, **DeRemer DL**. Power frequency electromagnetic fields and the capacitative calcium entry system in SV40-transformed Swiss 3T3 cells. *Radiation Research* 2000;153:699.
2. Ustun C, Farrow S, El-Geneidy, **DeRemer D**, Jillella A. A serious complication of allogeneic stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. *Clinical Medicine: Oncology* 2007: 191-94
3. Ustun C, Farrow S, **DeRemer D**, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. *Bone Marrow Transplant* 2007 Jun; 39(12):807-8.
4. Ustun C, **DeRemer DL**, Steele J, Forseen C, Fisher JF, Jillella AP. Fatal breakthrough Aspergillus fumigatus and Candida glabrata infections in a leukemia patient on posaconazole prophylaxis. *Int J Antimicrob Agents*. 2008 Oct; 32(4):365-6.
5. Ustun C, Kalla A, Farrow S, **DeRemer DL**, Jillella A. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation. *Am J Hematol*. 2008 Oct; 83(10):825-7
6. **DeRemer DL**, Natarajan K, Ustun C. Nilotinib (Tasigna®): A second generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. *Clin Ther*. 2008 Nov;30(11):1956-75.
7. Ustun C, **DeRemer DL**, Jillella A, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. *Expert Opinion Investig Drugs* 2009 Oct;18(10):1445-56.

8. Adams VR, **DeRemer DL**, Stevich B, Mattingly C, Gallt B, Subramanian T, Troutman HM, Speilmann HP. Anticancer activity of novel unnatural synthetic isoprenoids. *Anticancer Res.* 2010 Jul;30(7):2505-12.
9. Lewis G, Hall P, Eisa N, **DeRemer DL**, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high dose cytarabine consolidations and thus do not require prophylaxis. *Acta Haematologica* 2010 Nov 12;124(4):206-213
10. Ustun C, Jillella A, Shah R, Sterling K, **DeRemer DL**, et al. Second allogeneic stem cell transplantation from different donor improves severe steroid-resistant gut GVHD. *Bone Marrow Transplant* 2010 Nov;45(11):1658-60
11. Willis LM, Somanath PR, El-Remessy AB, **DeRemer DL**, Fagan SC. Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence. *Clin Science* 2011 Apr; 120 (8):307-19
12. **DeRemer DL**, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of chronic myeloid leukemia. *Cancer Manag and Res.* 2011 Mar 10;3:65-78.
13. Ustun C, **DeRemer DL**, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis. *Leukemia Res.* 2011 Sep;35(9):1143-52
14. Hammadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison, D, Speir E, **DeRemer D**, Kota V, Jillella A, Craig M, Awan F. Intermediate –versus low dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma patients treated with novel induction therapies. *Biol Blood Marrow Transplant.* 2012 Jul;18(7):1128-35
15. Awan F, Kochuparambil ST, **DeRemer D**, et al. Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization. *J Oncol* 2012;2012: 931071
16. Al-Husein B, Abdalla M, Trepte M, **DeRemer DL**, Somanath PR. Anti-angiogenic therapy for cancer: An update. *Pharmacotherapy.* 2012 Dec;32(12):1095-111.
17. **DeRemer DL**, Katsanevas K, Bradley A, Awan F. Romiplostim resistance in secondary failure of platelet recovery (SFPR). *J Oncol Pharm Pract* 2013 Dec;19(4):369-72
18. Bradley A, Devine M, **DeRemer DL**. Brentuximab vedotin: A novel antibody-drug conjugate. *Am J Health Syst Pharm.* 2013 Apr 1;70(7):589-97

19. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, **DeRemer D**, Jillella A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. *Bone Marrow Transplant* 2013 Oct;48(10):1279-84
20. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, **DeRemer DL**, Somanath PR. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression *in vitro* and *in vivo*. *Oncotarget* 2014 15;5(3):775-87.
21. Bradley A, Evans S, **DeRemer DL**, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? *J Oncol Pharm Pract.* 2015 Dec;21(6):425-32.
22. Clark SM, Clemmons A, Schaack L, Garren J, **DeRemer DL**, Vota V. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. *J Oncol Pharm Pract.* 2016 Jun;22(3):416-22.
23. Hartranft M, Clemmons A, **DeRemer DL**, Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. *J Oncol Pharm Pract. J Oncol Pharm Pract.* 2017 Jan;23(1):10-17
24. **DeRemer DL**, Clemmons AB, Orr J, Clark SM, Gandhi A. Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting. *Pharmacotherapy.* 2016 Feb;36(2):218-29.
25. Mangonkar A, Xu H, Moshin J, Mansour J, Chintalapally R, Keen R, Mondal AK, **DeRemer D**, et al. Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. *J Community Support Oncol.* 2016 Feb;14(2):66-71.
26. Evans SS, Gandhi AS, Clemmons AB, **DeRemer DL**. Clinical and cost comparison evaluation of inpatient versus outpatient administration of EPOCH-Containing regimens in Non-Hodgkin lymphoma. *J Pharm Pract.* 2016 Jul 18. pii: 0897190016659210. [Epub ahead of print]
27. Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, **DeRemer DL**, et al. The importance of research and scholarly activity in pharmacy training. *Pharmacotherapy.* 2016 Dec;36(12):e200-e205.
28. Andrick B, Alwahibi A, **DeRemer DL**, Quershi S, Khan R, Bryan L, Somanath PR, Pantin J. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukemia patients receiving ibrutinib. *Br J Haematol.* 2017 Jul 24 [epub ahead of print]
29. Gwynn ME, **DeRemer DL**. The emerging role of PD-1/PD-L1 targeting immunotherapy in the treatment of metastatic urothelial carcinoma. *Ann Pharmacother.* 2018 Jan;52(1):60-68.

30. Clemmons, AB, Orr, J, Andrick, B, Gandhi, A, Sportes, C, and **DeRemer, DL**. Randomized placebo controlled trial of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the FOND-O Trial. *Biology of blood and marrow transplantation. Biol Blood Marrow Transplant.* 2018 Oct;24(10):2065-2071.
31. Glode AE, Holle L, Nubla J, Minjock M, Egerton N, LeFebvre K, Reff M, **DeRemer D** Collaboration leads to oral chemotherapy education. *J Adv Pract Oncol* 2018;9(7):755–756.
32. Phillips BB, Newsome AS, Bland CM, Palmer R, Smith K, **DeRemer DL**, Phan SV. Evaluation of a pharmacy capstone course to develop patient evaluation skills utilizing the Pharmacists' Patient Care Process. *Am J Pharm Educ.* – Accepted for publication January 2019.

NON-PEERED REVIEWED

1. Adams VR, **DeRemer, DL**, Kilbridge JF. Apoptosis: Novel Molecular Targets in Cancer Therapy, Clinical Focus on Bcl-2. *Oncology Special Edition* Dec 2004.
2. **DeRemer DL**. Blincyto® (blinatumomab) for patients with Philadelphia chromosome-negative relapsed or refractory B-Cell precursor acute lymphoblastic leukemia. Submitted to *Pharmacy Practice News* March 2015.
3. **DeRemer DL**. Empowering Community Pharmacists as Health Consultants: Chemotherapy-Induced Nausea and Vomiting. *Inside Patient Care*. December 2015.

BOOK CHAPTERS

1. Gerson SL, Bhalla KN, Grant S, Natarajan K, Grant S, Creger RJ, **DeRemer D**. *Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies*. In: *Hematology: Basic Principles and Practice* (eds Hoffman R, Silberstein LE, Shattil SJ, et al.) 5th edition. Elsevier, Philadelphia, PA. 2008, p 839-873.
2. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York. 2011 p143 -150.
3. **DeRemer DL**, Manasco KB, Fagan SC. *Research: Becoming a Scholar*. In: Murphy JE (ed) *American College of Clinical Pharmacy Resident Survival Guide*. Lenexa, KS, 2011.

4. **DeRemer DL.** Drug and Food Interactions with Tyrosine Kinase Inhibitors. In: Ustun C and Popat UR (eds): *Chronic Myeloid Leukemia: From Daily Management to Complicated Issues*. New York, NY: Nova Science Publishers; 2014 pp. 251-262.
5. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 2nd edition. McGraw-Hill., New York. 2015.
6. **DeRemer DL** *Leukemias*. In: Sutton NAPLEX Review Guide. 3rd edition. McGraw-Hill., New York. 2018.
7. **DeRemer DL,** Higgins T: Acute Leukemias. In *Pharmacotherapy: A pathophysiologic approach*. (11th edition), Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds, McGraw-Hill, New York, NY (submitted 2019)

SECTION EDITOR

1. **DeRemer DL (section ed)** Barnett C, Malara J, Kimmel J. Breast Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
2. **DeRemer DL (section ed)** Mach CM, Hall TR. Endometrial Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
3. **DeRemer DL (section ed)** Crane EK. Ovarian Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
4. **DeRemer DL (section ed)** Berman T, Smith JA. Cervical Cancer. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill; 2019.
5. **DeRemer DL (section ed)** Saadeh C, Ottney A. Management of Treatment Complications. In: O'Connell M, Smith JA. eds. *Women's Health Across the Lifespan, 2e* New York, NY: McGraw-Hill;2019,

HANDBOOKS

1. Adams, V.R., **DeRemer, DL,** Holdsworth, MT. *Guide to Cancer Chemotherapeutic Regimens*. McMahan Publishing, New York, NY 2004
2. Adams, V.R., **DeRemer, DL,** Holdsworth, MT. *Guide to Cancer Chemotherapeutic Regimens*. McMahan Publishing, New York, NY 2005
3. Adams, V.R., **DeRemer, DL,** Holdsworth, MT. *Guide to Cancer Chemotherapeutic Regimens*. McMahan Publishing, New York, NY 2007

4. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2008
5. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2009
6. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2010
7. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2011
8. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2012
9. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2013
10. Adams, V.R., **DeRemer, DL**, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens. McMahon Publishing, New York, NY 2014
11. Adams, V.R. **DeRemer DL**, Bernhardt, MB. Guide to Cancer Therapeutic Regimens. McMahon Publishing, New York, NY 2017.

ABSTRACTS/POSTERS

1. Liewer SE, Hecht KA, Smith, CA, **DeRemer DL**, Adams VR, et al. Gelclair® for the treatment chemotherapy induced stomatitis in transplant and hematology patients: An interim analysis. Blood. 2004 Nov 16;104: 5317
2. Gallt RR, Mattingly CA, **DeRemer DL**, Adams VR. Determination of in vitro growth inhibition by novel farnesyl diphosphate analogues. American College of Clinical Pharmacy (ACCP) Annual Meeting 2005 San Francisco, CA. Abstract #511
3. **DeRemer DL**, Mattingly CA, Adams VR. In vitro interaction between topotecan (TPT) and paclitaxel (PAC) in three human ovarian cancer cell lines. ACCP Annual Meeting 2005 San Francisco, CA. Abstract #245
4. Kendrick A, Lake B, **DeRemer D**, Fain H, Farrow S, Ustun C, and Jillella A. Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell transplantation (HSCT). Presented at the 2007 American Colleges of Clinical Pharmacy Annual Meeting Denver, CO; October 15, 2007. Abstract #353.

5. Kendrick A, **DeRemer DL**. Evaluation of institutional BMT program compliance with recommended post-hematopoietic stem cell transplant (HSCT) vaccination guidelines. Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007
6. Fussell J, Boyle K, Kuth J, **DeRemer DL**, Ustun C. Review of institutional use of prophylactic voriconazole and posaconazole in patients with hematological malignancies. Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007.
7. Stevich B, Mattingly C, **DeRemer DL**, Spielmann P, Adams V. Targeting Ras with false prenyl analogs. Presented at 2008 American Colleges of Clinical Pharmacy (ACCP) Annual Meeting Louisville, KY; October 2008.
8. Carbonell C, **DeRemer DL**. Institutional analysis of rasburicase in the management of tumor lysis syndrome. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008.
9. Nestor MA, **DeRemer DL**. Evaluation of outcomes in acute promyelocytic leukemia patients receiving ATRA (All-trans Retinoic Acid). Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008
10. Almeter PJ, Robinson T, **DeRemer DL**. Institutional evaluation of vancomycin in neutropenic patients. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando, FL. December 2008.
11. Maciuleviciute E, Davis W, **DeRemer DL**. Evaluation of hypertension management bevacizumab treated patients. Presented at the 2008 University Health Consortium Pharmacy Council Resident Poster Session, Orlando, FL. December 6, 2008
12. Graham CR, Butterfield J, **DeRemer DL**. Impact of peptide nucleic acid fluorescence in situ hybridization (PNA FISH)-based identification of Candida species on antifungal utilization. Presented at the 2009 University Health Consortium Pharmacy Council Resident Poster Session, Las Vegas, NV. December 5, 2009
13. Mebel E, McAllister J, **DeRemer DL**. Evaluation of plerixafor on stem cell collection prior to an autologous hematopoietic stem cell transplant (aHSCT). Presented at 2009 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV. December 2009.
14. Awan F, **DeRemer D**, Mebel E, et al. Utility of plerixafor in addition to chemotherapy and G-CSF mobilization regimens. Blood (American Society of Hematology (ASH) Annual Meeting) 2010;116: 4443.

15. Katsanevas K, Ajiboye V, **DeRemer DL**. Evaluation of pegfilgrastim for primary prophylaxis for of neutropenic fever. Presented at the 2010 University Health Consortium Pharmacy Council Resident Poster Session, Anaheim, CA. December 4, 2010
16. Kochuparambil T, **DeRemer DL**, Mebel ER, Jillella AP, Awan F. Optimizing the efficacy of plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF. Presented at the 2011 American Society for Blood and Marrow Transplantation (ASBMT) Meeting. Honolulu, HI. February 17-21, 2011
17. Stoudenmire LL, Trepte M, McCracken C, Katsanevas K, **DeRemer DL**. Evaluation of obesity on achieving remission following induction therapy for acute myelogenous leukemia. ACCP Annual Meeting 2011 Pittsburgh, PA. Abstract # 448
18. Morrison DD, Kochuparambil ST, **DeRemer DL**, et al. Clinical Practice Guideline for the treatment of BK-Virus induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. Volume 18 Issue 2. Presented at the American Society of Bone Marrow Transplant (ASBMT) Annual Meeting at San Diego, CA. Feb 1-5, 2012.
19. Hamadani S, Kochuparambil ST, Osman S, Speir E, Craig M, **DeRemer D**, et al. Intermediate-versus low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization in patients with multiple myeloma treated with novel induction chemotherapies – A multicenter analysis. Blood (ASH Annual Meeting Abstracts), Nov 2011;118: 313.
20. Katsanevas K, Al-Husein B, **DeRemer D**, Shenoy S. Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy? Presented at the 2012 Hematology/Oncology Pharmacist Association (HOPA) Meeting, Orlando, FL. March 22, 2012.
21. **DeRemer DL**, Katsanevas K, Forehand C, et al. Successfully integrating translational research into a PGY2 research project. Presented at the 2012 ASHP National Residency Preceptors Conference in Washington, DC. August 17, 2012.
22. **DeRemer DL**, Katsanevas K, Lou U, et al. Src inhibition with dasatinib offers potential benefit for prostate cancer. Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.
23. Evans S, **DeRemer D**, Bradley A. Intravenous busulfan pharmacokinetics in conditioning regimens for allogeneic stem cell transplantation: impact of dosing weight on clinical outcomes. Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA. September 6, 2012.
24. Awan F, Kochuparambil ST, Craig M, Cumpston A, Leadmon, S, Watkins K, **DeRemer D**, Pantin J, Kota V, Jillella AP, Hamadani. Intermediate-Dose Cyclophosphamide Versus Plerixafor and

Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies – A Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 4409

25. Steinbach A, Goc A, **DeRemer D**, Shenoy S. Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis. Presented at the 9th Annual HOPA Conference in Los Angeles, GA. March 21, 2013.
26. Schaack L, Clark SM, Clemmons AB, **DeRemer DL**, Kota V. Characterization of chemotherapy induced nausea and vomiting outcomes in patients receiving melphalan-containing conditioning chemotherapy for autologous hematopoietic stem cell transplant. Presented at 2013 ACCP Annual Meeting in Albuquerque, NM. Abs #347
27. Clark SM, Schaack L, **DeRemer D**, Kota V, Clemmons AB. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Feb;20(2 Suppl):S287.
28. Hartranft ME, **DeRemer DL**, Kolhe R, Phillips BG. Investigation of epigenetic modifications in obese and non-obese acute myeloid leukemia patients. Presented at 10th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), New Orleans, LA. Resident Trainee Poster #125
29. **DeRemer DL**, Hartranft ME, Mondal A, Kolhe R, Meagher R, Phillips BG. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response. Presented at 2014 ACCP Annual Meeting in Austin, TX. Abs#442.
30. Evans S, Clemmons AB, Gandhi A, **DeRemer D**. Clinical and economic evaluation of inpatient versus outpatient administration of EPOCH-containing regimens in Non-Hodgkin lymphoma. Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Austin, TX. Resident Trainee Poster #32
31. Orr J, Clemmons AB, Gandhi A, **DeRemer D**. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of CINV in hematology patients receiving highly emetogenic chemotherapy regimens (The FOND-O Study). Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident Trainee Poster #100
32. Andrick B, **DeRemer D**, Abdul Sater- H, Bollag R, Pantin J, Shenoy S. Pneumococcal vaccine response in chronic lymphocytic leukemia patients with ibrutinib. Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident Trainee Poster #27

33. Andrick B, Alwhaibi A, **DeRemer D**, Quershi, Khan R, Shenoy S, Pantin J. Antibody response to pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving ibrutinib. *Blood* 2016 128:5597.
34. George TJ, Starr JS, Parkeh HD, Ivery AM, Dang LH, Daily KC, Allegra CJ, **DeRemer DL**, et al. Final toxicity results from a phase II study of 5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma. 2018 Gastrointestinal Cancers Symposium ASCO Meeting, abstract #504.
35. Gwynn M, **DeRemer D**, Saunders K, Parikh J, Bollag R, Clemmons AB. Evaluation of immune-mediated adverse events after influenza vaccination in cancer patients receiving immune checkpoint inhibitors. Presented at Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, Denver, CO. Resident Trainee Poster #71
36. George TJ, Starr JS, Parkeh HD, Ivery AM, McGorray SP, Wang Y, Dang LH, Daily KC, Allegra CJ, **DeRemer DL**, et al. Final results from a phase II study of 5-fluorouracil, oxaliplatin, and dasatinib (FOLFOX-D) in previously untreated metastatic pancreatic adenocarcinoma. *J Clin Oncol* 36, 2018 (suppl; abstr 4124)
37. Parekh H, **DeRemer DL**, Hitchcock K, et al. A phase II, open-label pilot study evaluating the safety and activity of nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study). *J Clin Oncol* 37, 2019 (suppl 4; abstr TPS476)

GRANTS

1. *Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell transplantation.* University of Georgia Randy Ellison Cancer Research Grant. Project period 10/06-5/07. (Primary Investigator, 50% effort). Total award \$2000
2. *Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy?* University of Georgia Translational Research Initiative Grant. Project period 10/11-07/12. (Sub-Investigator, 5% effort). Total award \$7500
3. *Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis.* Submitted 9/12 for University of Georgia Translational Research Initiative Grant. Project period 10/12-07/13. (PI, 5% effort). Total award \$10,000
4. *Examining TGF β and Integrin α v β 3 Expression in Early and Aggressive Human Prostate and Bladder Cancer Tissues as Biomarkers for early detection and as targets for therapy.* Project

period 2013-14. University of Georgia Translational Research Initiative Grant. (Sub-investigator, 5% effort). Total award \$10,000

5. *Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical outcome and drug response.* University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2014-2015. (PI, 75% effort). Total award \$4,500
6. *Pneumococcal vaccine response in chronic lymphocytic leukemia (CLL) patients receiving ibrutinib.* University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2015-2016. (PI, 75% effort). Total award \$4,000

CLINICAL TRIALS

1. A Phase IA/II, two-arm, multi-center, open-label, dose escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies. – Role: Institutional Sub-I. 2006-2008.
2. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the FOND-O Study. (NCT02635984)- Investigator Initiated Trial, Role: Institutional Sub-I. 2015-2017
3. An open-label study of rovalpituzumab tesirine in subjects with delta-like protein 3-expressing advanced solid tumors. Role: Institutional Sub-I. 2017-current
4. A Phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment. Role: Institutional Sub-I. 2017-2018
5. A Phase 1/2, Open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors. Role: Institutional Sub-I. 2017-current
6. A Phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors. Role: Institutional Sub-I. 2017-current
7. A Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination with immune therapies in subjects with advanced or metastatic malignancies. Role: Institutional Sub-I. 2017 –current

8. A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors. Role: Institutional Sub-I. 2018-current.
9. Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. Institutional Role: Sub-I. 2018-current.
10. Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors. Institutional Role: Sub-I. 2018-current.
11. A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors. Institutional Role: Sub-I. 2018-current.
12. Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001) Institutional Role: Sub-I. 2018-current.

OTHER SCHOLARLY/CREATIVE WORKS

1. In collaboration, designed – Required Competency Areas, Goals, and Objectives for PGY2 Oncology Pharmacy Residencies (2017) - <http://www.ashp.org/DocLibrary/Residents/Oncology-Pharmacy-2016.pdf>

HONORS AND AWARDS

2019	Elected to Fellowship in HOPA
2015	Elected to Fellowship in ACCP
2014	ACCP Annual Meeting – Best Paper Award
2014	ACCP Hematology/Oncology PRN FIT Program Scholarship Recipient
2012	Georgia Society of Health-System Pharmacists (GHSP) Outstanding Practitioner of the Year
2005	ACCP Research Travel Award
2003	Clinical Pharmacy Residents Program Educational Grant- Pfizer
2003	University of Kentucky Medical Center Resident of the Month
1996	Howard Hughes Research Institute Research Award

ADMINISTRATIVE ACTIVITY/COMMITTEESUniversity of Florida Health College of Pharmacy

2018-present	Member, Promotion and Tenure Committee
2018-present	Member, Admissions Committee

University of Florida Health Cancer Center

2017-present	Member, Scientific Review and Monitoring Committee (SRMC)
2017-2018	Member, Data Integrity and Safety Committee (DISC)
2017-present	Member, Cancer Therapeutics and Host Response Committee
2017-present	Member, Translational Research Accelerator Committee

University of Georgia College of Pharmacy

2016-2017	Academic and Professionalism Committee
2013-2017	Student Wellness Committee
2013-2017	Students Oncological Advocates in Pharmacy (SOAP)- Faculty Advisor
2014-2016	Academic House Host – Augusta PGY3 students
2014-2016	Chair, Clinical Tracks Work Group
2010- 2012	UGA Faculty alternative delegate for American Association of Colleges of Pharmacy (AACP)
2009-2013	Member, Scholarship and Awards Committee 2012-2013 Chair
2007-2009	Member, Faculty Development Committee
2006-2009	Admissions Committee

Augusta University (formerly known as -Georgia Regents University (GRU))

2012-2017	Member, Cancer Institutional Review Board (C-IRB)
2012-2017	Associate Member GRU Cancer Center
2008-2017	GRU/UGA Pharmacy Residency Advisory Committee (RAC) member
2006-2017	GRU BMT/Hematologic Malignancies Committee
2005-2017	GRU Oncology Pharmacy and Therapeutics Subcommittee
2005-2006	Medical College of Georgia (now GHSU) Palliative Care Committee

University of Kentucky

2003-2005	UK Oncology Pharmacy and Therapeutics Subcommittee
2003-2004	UK Medical Center Medication Use Evaluation Subcommittee

2002-2003 UK College of Pharmacy Admissions Committee (Resident member)

PROFESSIONAL ACTIVITY

2017- present American Society of Clinical Oncology (ASCO) member

2015-present National Community Oncology Dispensing Association (NCODA)

- Executive Advisory Board (2016-2017)
- Advisory Board (2017-2018)

2006-present Georgia Health Systems Pharmacy (GSHP) member

2006-present Hematology/Oncology Pharmacy Association (HOPA) member

- President-Elect, Board of Directors (2019-2020)
 - Public Policy Committee
 - Advocacy Council
 - Finance Committee
- Oncology Pharmacy Competency and Certificate Program Task Force (2018- current)
- Vice-Chair, Tools and Resources Committee (2017-2019)
- Oral Chemotherapy Education Task Force (2016-present)
- Board of Directors, Member at Large (2015- 2017)
 - Advocacy HOPA On the Hill Day Washington, DC 2015, 2016, 2017, 2019
 - Committee Restructuring Task Force (2016)
 - Board Liaison, Practice Management (2016-2017)
 - Board Liaison, Annual Program Committee (2016-2017)
 - Board Liaison, Membership Committee (2015-2016)
 - Board Liaison, Publications Committee (2015- 2016)
 - BIG idea Taskforce (2015-2016)
- Vice Chair, Recognition Committee, (2014- 2015)
- Research and Abstract Review Committee (2010-2013)
- Poster Reviewer (2009-2012)

2002-present American College of Clinical Pharmacy (ACCP) Associate member

- Research Committee, member (2015-2016)
- Hematology/Oncology PRN Chair (2015-2016)
- Hematology/Oncology PRN Chair Elect (2014-2015)
- Hematology/Oncology PRN program committee (2014-2016)
- Academy Resident Mentor participant (2013- current)
 - Mentee – Julianne Orr, Pharm.D. (PGY1 Resident, Greenville Health System)

- Mentee- Sarah Hayes, Pharm.D. (PGY1 Resident, N. Memorial Medical Center)
- Mentee- Deeter Neuman, Pharm.D. (PGY1 Resident, University of Michigan)
- Mentee – Manuel Cortez, Pharm.D. (PGY2 Oncology Resident, University of Chicago)
- Mentee – Aaron Stewart, Pharm.D. (PGY1 Resident, VA Sierra Nevada Health Care)
- Student CV Reviewer (2012- current)
- Student Trivia Game Writer – Oncology (2010-2011) and (2016-2017)
- Hematology/Oncology PRN Member (2003- current)

2012-2014	American Society for Blood and Marrow Transplantation – Affiliate member
2002-2005	Kentucky Health System Pharmacists (KSHP) member
2001-present	American Society of Health System Pharmacists (ASHP)
1998-2002	Kappa Psi Pharmaceutical Fraternity

CONSULTING

2013-2016	Merck – Speakers bureau
2010-2012	Georgia Department of Public Health - Georgia Cancer State Aid Program Formulary Reviewer

SCIENTIFIC JOURNAL REFEREE AND BOOK REVIEWER

Books

Pharmacotherapy Principles and Practice -3rd edition
Chapter- *Malignant Lymphomas*

Journals

2019 –present	<i>Clinical Lymphoma, Myeloma, and Leukemia</i>
2019-present	<i>Journal of American College of Clinical Pharmacy (JACCP)</i>
2017-present	<i>Supportive Care in Cancer</i>
2017-present	<i>Journal of Pharmacy Technology</i>
2016-present	<i>BMJ Open</i>
2014-present	<i>Journal of Hematology/Oncology Pharmacy</i>
2013-present	<i>Annals of Pharmacotherapy</i>
2013-present	<i>Pharmacotherapy</i>
2012-present	<i>American Journal of Health Systems Pharmacists</i>

EDITORIAL ACTIVITY

Computer Apps for Oncology Professionals

2014- 2016 Essential oncology/McMahon Publishing

COMMUNITY SERVICE

2013-2017 Upward Sports Coach (Soccer, Basketball)

2009-2017 Leukemia and Lymphoma Society – Light the Night fundraising GRU
team member

2003-2005 Life Adventure Camp

1998-2002 Faith Pharmacy Volunteer

1992-1996 King of the Bluegrass Flag Football Tournament for Big Brothers/Big
Sisters